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Abstract: Toll-like receptor (TLR) activation is
dictated by a number of factors including the li-
gand itself and the localization of the receptor, in
terms of expression profile and subcellular local-
ization and the signal transduction pathway that has
been activated. Recent work into TLR signal trans-
duction has revealed complex regulation at a num-
ber of different levels including regulation by phos-
phorylation, targeted degradation, and sequestra-
tion of signaling molecules. Here, we describe
recent advances that have been made in our under-
standing of how TLR signaling is regulated at the
biochemical level. J. Leukoc. Biol. 80: 220–226;
2006.
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INTRODUCTION
Toll-like receptors (TLRs) play a critical role in the evolution-
ary conserved innate immune response and represent our first
line of defense against invading pathogens. TLRs are activated
in response to a broad spectrum of pathogen-associated mo-
lecular patterns (PAMPs) ranging from bacterial and viral
components to fungal and protozoal molecules. The ability to
orchestrate an appropriate primary immune response to a vast
array of diverse PAMPs is key in our ability to ward off
potential pathogenic organisms. The capacity not only to re-
spond appropriately but also to self-regulate host responses to
invading pathogens is vital in our ability to mount an appro-
priate primary immune response.
To date, 11 human TLRs and 13 mouse TLRs have been
identified. It has been shown that TLRs are activated by
specific PAMPs and that the ability of specific TLRs to het-
erodimerize adds further to the diverse range of pathogens that
may be recognized [1]. For example, TLR1, -2, -4, -6, and -10
recognize lipids. Specifically, lipopolysaccharides (LPS) from
Gram-negative bacteria are recognized by TLR4. TLR2, in
combination with TLR1 or TLR6, recognizes triacyl lipopep-
tides and diacyl lipopeptides, respectively. In contrast to the
plasma-membrane localization of the aforementioned TLRs,
the so-called antiviral TLRs, TLR3, -7, -8, and -9, are endo-
somally localized, membrane-bound receptors. TLR3 recog-
nizes double-stranded (ds)RNA, which is produced from many
viruses during replication. TLR7 recognizes synthetic imida-
zoquinoline-like molecules, guanosine analogs such as loxor-
ibine, and single-stranded (ss)RNA derived from viruses such
as human immunodeficiency virus. TLR8 mediates the recog-
nition of imidazoquinolines and ssRNA. TLR9 recognizes bac-
terial and viral CpG DNA motifs. In addition, a third class of
TLRs has been defined, sensing protein ligands. Specifically,
TLR5 recognizes flagellin, and human TLR11 recognizes uro-
pathogenic Escherichia coli [2]. Recently, the first defined
ligand for TLR11 has been described in mice as a profilin-like
protein, a class of actin-binding proteins present in apicom-
plexan protozoa [3, 4]. After recognition of PAMPs, a cascade
of intracellular signaling events is activated, which culminates
in the induction of proinflammatory cytokines such as tumor
necrosis factor  (TNF-), interleukin (IL)-6, IL-1, and IL-
12. In addition, antiviral type I interferons (IFNs; IFN- and
multiple IFN-) are induced by TLR3, -4, -7, -8, and -9.
Moreover, TLRs induce dendritic cell maturation, essential for
the induction of pathogen-specific adaptive immune responses
[5]. Activation of the intracellular signaling cascades is facil-
itated by the initial formation of multiprotein complexes con-
taining the TLR and proximal cytoplasmic Toll/IL-1 receptor
(IL-1R; TIR)-containing adaptor molecules such as myeloid
differentiation primary response protein 88 (MyD88), MyD88
adaptor-like (Mal), also known as TIR domain-containing
adaptor protein, TIR domain-containing adaptor-inducing
IFN- (Trif), and Trif-related adaptor molecule (TRAM) [6].
Herein, we describe recent advances in our understanding of
how the TLR signaling pathway may differentially regulate its
response, depending on the nature of the invading pathogenic
organisms. Also, we will focus on the inherent ability of our
immune system to self-regulate its response to PAMPs to avoid
exaggerated responses to pathogens, which may ultimately lead
to pathophysiological states.
THE TLR ECTODOMAIN
All TLRs are type I transmembrane receptors characterized by
a highly variable extracellular region containing a leucine-rich
repeat domain (LRR) involved in ligand binding and an intra-
cellular tail containing a highly conserved region, the TIR
homology domain, which mediates interaction between TLRs
and downstream signaling molecules. Although the molecular
structure of the TIR domains of TLR1 and TLR2 had been
defined [7], it became increasing important to characterize the
extracellular LRR with a view to expanding our understanding
of how ligands interact with TLRs. Recently, the crystal struc-
ture of the TLR3 ectodomain has been solved at 2.1 Å [8, 9].
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It is a large, horseshoe-shaped solenoid assembled from 23
LRR stabilized by asparagine residues in the 24-residue LRR
motif contributing to hydrogen-bonding networks. The ectodo-
main is heavily glycosylated with one face on the outer convex
surface completely devoid of any glycosylation. This region is
the predicted site for dsRNA binding. This is an important
finding, as it was previously thought that ligand binding oc-
curred solely at the inner-concave surface. In addition, the
nonglycosylated region within the concave surface contains
areas of positively charged residues, which are predicted to
provide a binding surface for dsRNA and may facilitate TLR3
dimerization. Given the complexity of the ectodomain, it is
possible that TLRs may bind different ligands at alterative sites
and thus, may impact on the assembly of the intracellular,
multiprotein-signaling complex. Thus, future studies will pro-
vide a clearer understanding of how TLRs recognize such a
diverse array of PAMPs.
Mutations have been reported in the ectodomain of TLR4.
For example, Asp299Gly and Thr399Ile polymorphisms in the
TLR4 ectodomain predispose to severe malaria [10], possibly
by impacting on ligand recognition. This is currently an intense
area of research and will expand our broader knowledge into
how we have selectively evolved to meet pathogenic chal-
lenges.
TLR LOCALIZATION AND ACCESSIBILITY
Given that all TLRs possess a LRR, a transmembrane region,
and a cytoplasmic domain, it was assumed initially that all
would be expressed at the cell surface. This has proven not to
be the case. Whereas TLR1, -2, -4, -5, and -6 are expressed on
the cell surface, TLR3, -7, and -9 are localized to intracellular
endosomal compartments. TLR8 appears to be localized pri-
marily, intracellularly with a small portion expressed on the
cell surface [11–16]. It is known that whereas the plasma
membrane-localized TLRs recognize PAMPs, unique to bacte-
rial and fungal cells, the intracellular TLRs recognize viral and
bacterial nucleic acids. It is possible that the intracellular
environment may facilitate ligand recognition by the intracel-
lular TLRs, possibly by ligand modification as a consequence
of lysosomal acidification, or perhaps the breakdown of late
endosomes or lysosomes may serve to release the nucleic acids
from the bacteria/virus. Recently, a number of studies have
attempted to address the mechanism by which differential
subcellular localization is achieved and the biological signifi-
cance thereof. A recent study has shown that TLR3 is targeted
intracellularly by a 23-amino acid sequence (Glu727–Asp749)
present in the linker region between the transmembrane do-
main and the TIR domain [17]. In contrast, the intracellular
localization of TLR7 is achieved by its transmembrane domain.
Despite differences in the mechanism by which they are local-
ized, both receptors actually colocalize preferentially near
phagosomes containing apoptotic cell particles [17]. Following
viral infection, phagocytes take up apoptotic-infected cells,
and lysosomal hydrolyases cause release of the virus-derived
RNAs from the intracellular compartments, thus facilitating
access of the intracellular TLRs to their respective RNA li-
gands. Although the viral RNA may be recognized by the
so-called antiviral TLRs [18], it must be noted that viral-
derived dsRNA may also be recognized by the cytosolic RNA
helicase retinoic acid-inducible gene-I, inducing type I IFN in
a TLR-independent manner [19, 20]. More recently, another
study has revealed that intracellular localization of TLR9 fa-
cilitates access to viral DNA and prevents recognition of self-
DNA [21]. It was shown that the transmembrane region of
TLR9, but not the linker TIR and tail regions, is responsible for
its intracellular localization. Moreover, a chimeric TLR,
TLR9N4C, comprised of the ectodomain of TLR9 and trans-
membrane and cytosolic regions of TLR4, localizes to the
plasma membrane. Although the chimeric receptor responds
equally to CpG when compared with TLR9, the chimeric
TLR9N4C does not sense viral DNA. This is because the
chimeric receptor does not have access to the nucleic acids in
the viral particles. Furthermore, the chimeric TLR, relocalized
to the plasma membrane, recognizes self-DNA. Taken together,
this suggests first that despite both TLRs being functional, viral
particles must be degraded to expose the nucleic acids and
facilitate signal activation by TLR9 and second, that intracel-
lular localization of TLR9 prevents its activation by self-DNA,
as it does not come into contact with self-DNA. Moreover, it
has been shown previously that DNase I is secreted into serum
to promote degradation of self-DNA, and mice lacking DNase
I develop a lupus-like disease [22, 23]. Adding further to the
complexity regarding the interaction of antiviral TLRs with
their respective ligands is the recent finding that self-DNA is
also recognized by a novel, TLR-independent mechanism,
resulting in activation of the innate immune system [24].
Specifically, DNase II is expressed predominantly in macro-
phages and cleaves the DNA of engulfed apoptotic cells and
the nuclei expelled from erythroid precursor cells during eryth-
ropoiesis; DNase II-deficient mice have been shown to accu-
mulate DNA in their macrophages with concomitant IFN-
production and fetal lethality [24, 25]. It is surprising that it
was shown that ablation of TLR3, TLR9, MyD88, or Trif had no
effect on the lethality of DNase II-deficient mice, suggesting
that the self-DNA is recognized by a TLR-independent mech-
anism, yet to be determined [24]. From these studies, it is clear
that ligand availability and/or receptor compartmentalization
are mechanisms by which TLR signaling has evolved to self-
regulate, and TLR localization is key to this phenomenon.
Moreover, in an effort to down-regulate host responses to
pathogens, TLRs have evolved mechanisms to control or self-
regulate its response to pathogens. For example, the TLR itself
may be degraded, thereby making it unavailable for subse-
quent ligand activation, or its expression may be inhibited by
anti-inflammatory cytokines. Targeted degradation is achieved
via polyubiquitination and subsequent degradation by the 26S
proteasome. TRIAD3A was a molecule found to bind the
cytoplasmic domain of TLR4 and TLR9, but not TLR2, and to
promote the ubiquitination and degradation of TLR4 and
TLR9, but not TLR2 [26]. Moreover, overexpression of
TRIAD3A reduced TLR4- and TLR9-mediated nuclear factor
(NF)-B activation in response to LPS and CpG but not pI:C
[26]. Anti-inflammatory cytokines also have the ability to down-
regulate TLR expression. For example, transforming growth fac-
tor- (TGF-) suppresses the expression of TLR4 [27].
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ADAPTOR MOLECULES
As outlined above, there are four functional adaptor molecules:
MyD88, Mal, Trif, and Tram [6]. Each of these molecule
interacts heterophilically with defined TLRs. As shown in
Figure 1, MyD88 is the central adaptor molecule interacting
with all TLRs except TLR3. Upon ligand activation, MyD88
recruits members of the IRAK family and TRAF6. IRAK then
becomes phosphorylated and dissociates from MyD88, which
results in TRAF6 being activated, followed by TAK1/TAB1/
TAB2/TAB3 complex formation and activation via K63-linked
ubiquitination. Activated TAK1 complex then activates the
IKK complex consisting of IKK, IKK, and IKK/NF-B
essential modulator, which catalyze IB phosphorylation. IB
is then destroyed by the proteasome pathway, allowing NF-B
to translocate into the nuclei, resulting in proinflammatory
cytokine production [1]. This is termed the MyD88-dependent
pathway. The second adaptor molecule, Mal, may also be
involved in this pathway, and it is thought that Mal acts as a
bridging adaptor between TLR4, TLR1/2, TLR2/6, and MyD88
[1]. In addition, the Trif-dependent pathway may be activated,
as is the case for TLR3 and TLR4. Whereas Tram is thought to
act as a bridging adaptor between Trif and TLR4 [28], Trif
interacts directly with TLR3 [29]. Activated Trif recruits TBK1
and together with IKKi, mediate IRF3 phosphorylation, dimer-
ization, and nuclear translocation mediating type 1 IFN induc-
tion [30, 31]. Trif also interacts with TRAF6 and RIP1, which
mediate NF-B activation [32–34].
Intracellular signaling instigated via the adaptor molecules
may be regulated in a number of ways, including protein
phosphorylation, degradation, interaction with inhibitory adap-
tor molecules, and sequesteration. For example, MyD88s in-
hibits IL-1 and LPS-induced NF-B activation. Specifically,
overexpression of MyD88s favors formation of MyD88s-MyD88
heterodimers over MyD88 homodimers. In the presence of
these heterodimers, IRAK1 is recruited via the death domain
Fig. 1. Regulation of TLR signaling pathways. Whereas TLR4 activates the MyD88-dependent and the Trif-dependent pathways, TLR3 activates the
Trif-dependent pathway only. MyD88 recruits IL-1R-associated kinase 4 (IRAK4) and TNF receptor-associated factor 6 (TRAF6) upon ligand stimulation. TRAF6
activates the TGF--activated protein kinase 1 (TAK1)/TAK-1-binding protein-1 (TAB1)/TAB2/TAB3 complex via K63-linked ubiquitination (UB). Activated
TAK1 complex then activates the inhibitor of B (IB) kinase (IKK) complex, which catalyzes IB phosphorylation and degradation by the proteasome pathway,
thus allowing NF-B to translocate into nuclei. NF-B and activated protein 1 (AP-1) control inflammatory responses by inducing proinflammatory cytokines, such
as TNF, IL-1, IL-18, and IL-6. TLR4 also recruits TRAM and Trif, which interacts with Traf family member-associated NF-B activator-binding protein (TBK1),
and TBK1, together with inducible IKK (IKKi), mediates phosphorylation of IFN regulatory factor 3 (IRF3). Phosphorylated IRF3 is dimerized and translocated
into the nucleus to bind DNA. Trif also interacts with TRAF6 and receptor-interacting protein kinase 1 (RIP1), which mediate NF-B activation. Activation of
IRF3, NF-B, and AP-1 is required for induction of type I IFN, particularly IFN-. TLR3, which resides in endosomal vesicles, uses Trif but not MyD88, mediating
the induction of type 1 IFNs. TLR signaling is negatively regulated by suppressor of cytokine signaling 1 (SOCS-1), Flightless I homologue (Fliih), ST2, Triad3A,
Traf1, A20, IRAK-M, IRAK-1c, a short form of MyD88 (MyD88 s), and -arrestin, as illustrated.
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(DD), but it is no longer phosphorylated. MyD88s inhibits the
ability of IRAK4 to phosphorylate IRAK1, as unlike full-length
MyD88, it is unable to interact with IRAK4 [35]. As the kinase
is not recruited to the receptor complex, signaling is inhibited.
Recently, we have shown that the orphan receptor ST2L neg-
atively regulates IL-1R and TLR4-mediated signaling via
adaptor sequesteration [36]. Specifically, we have shown that
ST2L, a type I transmembrane protein with three extracellular
immunoglobulin-like domains and an intracellular TIR do-
main, interacts with and sequesters MyD88 and Mal, but not
Trif or IRAK. Moreover, a mutant form of ST2L with a mutated
proline residue in box 2 of the TIR domain, lost its inhibitory
activity. Thus, ST2L inhibits IL-1R and TLR4 signaling by
sequesteration of MyD88 and Mal via its TIR domain, thus
making them unavailable for signaling [36]. Another molecule,
Fliih, has been shown to modulate TLR signaling by interact-
ing with MyD88 and acting as a negative regulator [37]. Fliih
contains 16 copies of the LRR motif at its N-terminal region,
and the C-terminal regions are homologous to the gelsolin
family of actin-binding proteins.
Mal interacts directly with TRAF6 to mediate NF-B acti-
vation through TLR2 and TLR4 [38] via a putative TRAF6-
binding motif within Mal. Moreover, mutation of the TRAF6-
binding motif within Mal, generating MalE190A, inhibited
NF-B activation, p65-mediated transactivation of gene ex-
pression, and p42/p44 mitogen-activated protein kinase
(MAPK) activity. Thus, an intact TRAF6-binding motif within
Mal is essential for Mal to signal. It has also been shown that
Trif interacts with TRAF6 via a TRAF6-binding motif [34, 39].
Trif was found to mediate TLR3-induced activation of NF-B
via association with TRAF6 [34].
It has also been reported that MyD88, Trif, and TRAM
undergo phosphorylation [34, 40, 41], although the ramifica-
tions of phosphorylation remain to be elucidated. Recently, we
have shown that Mal is subject to tyrosine phosphorylation
[42]. Specifically, Mal may be tyrosine-phosphorylated at po-
sitions 86, 106, and 187 during TLR signaling. Moreover,
variants of Mal, in which the Tyr 86 or Tyr 187 is substituted
with phenylalanine, act as dominant-negative inhibitors of LPS
signaling. We identified the Tec kinase, Bruton’s tyrosine
kinase (Btk), as the kinase responsible for phosphorylating Mal
[42, 43]. These findings suggest that tyrosine phosphorylation
is necessary for Mal to signal, although further studies are
required to fully explore these possibilities.
More recently, we have shown that SOCS-1 negatively reg-
ulates TLR signaling by mediating the degradation of Mal [43].
Specifically, we have shown that after TLR2 and TLR4 stim-
ulation, Mal becomes phosphorylated by Btk and then Mal
interacts with SOCS-1, an E3 ligase, mediating Mal polyubiq-
uitination and subsequent degradation via the 26S proteasome.
Moreover, SOCS-1-deficient mice exhibit potentiation of Mal-
dependent p65 phosphorylation and NF-B transactivation,
leading to amplification of inflammatory signaling [43]. In
contrast to the delayed expression of MyD88s and ST2L,
targeted degradation of Mal by SOCS-1 represents a more rapid
mechanism of regulating TLR signaling.
These studies show that TLR signaling may be regulated by
alternative adaptor use, depending on the initial activation
signal. Thereafter, the adaptors may be regulated positively
and negatively by phosphorylation. Also, targeted degradation
following ubiquitination and interaction with negative regula-
tory molecules may impact on adaptor functionality. In addi-
tion, adaptor molecules may be down-regulated by anti-inflam-
matory cytokines. For example, it has been shown that TGF-
induces MyD88 degradation by the proteasome and so down-
regulates TLR signaling [44]. It is interesting that despite
phosphorylated MyD88 being detected in cell lysates following
LPS exposure [41], MyD88 is not subject to SOCS-1-mediated
degradation.
IRAKs
Four IRAK family members have been identified and are
characterized as having an N-terminal DD to facilitate inter-
action with MyD88 and a C-terminal kinase domain. Whereas
IRAK-1 and IRAK-4 are catalyically active, IRAK-2 and
IRAK-M are inactive as a result of an absence of key residues
in their respective kinase domains [45–48]. Upon activation of
TLR signaling, IRAK-1 and IRAK-4 are recruited to the
receptor complex. At the receptor, IRAK-1 associates with
Toll-interacting protein (Tollip), MyD88, and TRAF6, and
phosphorylation by IRAK-4 triggers IRAK-1 hyperphosphory-
lation and dissociation of IRAK-1 from the complex while still
maintaining its engagement with TRAF6.
IRAKs are subject to regulation at a number of levels
including interaction with inhibitory molecules and inhibition
of expression. A number of these inhibitory molecules are well
defined. For example, IRAK-M is an induced negative regula-
tor that blocks IRAK-4 activation and subsequent IRAK-1
phosphorylation [49]. Tollip itself has been regarded as an
inhibitory molecule. As stated above, Tollip interacts with
IRAK-1, and IRAK-1 autophosphorylation is suppressed in the
presence of Tollip. Following TLR stimulation, IRAK-1 phos-
phorylates Tollip, and this may lead to the release of Tollip
from the Tollip:IRAK-1 complex, thus overcoming negative
regulation [50]. More recently, studies have shown that Tollip
regulates the magnitude of inflammatory cytokine production in
response to IL-1 and LPS [51]. Specifically, Tollip-deficient
mice exhibited attenuated responses to the proinflammatory
cytokines, IL-6 and TNF- [51], suggesting that Tollip may
function in fine-tuning the response to cytokines.
More recently, an inhibitory splice variant of IRAK-1 was
identified [52]. Unlike IRAK-1, the spliced variant IRAK-1c
lacks kinase activity and cannot be phosphorylated by IRAK-4
but still retains its ability to interact with IRAK-2, MyD88,
Tollip, and TRAF6. Therefore IRAK-1c functions as a domi-
nant-negative by failing to be phosphorylated by IRAK-4 and
thus remains associated with Tollip and blocks NF-B activa-
tion. Also, two splice variants of murine IRAK2, namely
IRAK2c and IRAK2d, are inhibitory. Unlike IRAK2, these
variants lack a DD and inhibit LPS-induced NF-B activation
[53]. Moreover, treatment of the mouse macrophage cell line
RAW264.7 with LPS for 1 and 3 h resulted in an increase in
IRAK2c mRNA levels, indicating a possible negative-feed-
back loop [53].
There is another mechanism by which TLR signaling via
modulation of IRAKs involves its down-regulation at the
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mRNA level. Specifically, it has been shown that inhibition of
IRAK-1 expression at the mRNA and protein levels is the
mechanism by which Pam3Cys-SK43HCl-induced tolerance
via TLR2 is mediated [54]. A similar mechanism of decreased
IRAK-1 protein was evident following exposure of peritoneal
macrophages to the TLR7/8 ligand, R848 [55]. Moreover, this
mechanism of self-regulation appears to be ligand-specific, as
IRAK-1 mRNA and protein levels are normal in cells following
LPS-induced tolerance [54].
Recently, the crystal structure of the DD region of IRAK-4
was resolved to 1.7 Å [56] and represents our first insight into
the structural details of a member of the mammalian IRAK
family. The crystal structure reveals a six-helical bundle with
a prominent loop, which among IRAKs and Pelle, a Droso-
philia homologue, is unique to IRAK-4. This unique loop is
highly structured, comprised of an 11 amino acid stretch,
which may in the future serve as a potential site for the design
of inhibitory molecules of therapeutic value.
TRAF FAMILY
TRAF family members, comprising TRAF1–6, are proposed to
be the adaptor molecules linking upstream receptor signals to
gene activation. The TRAF proteins are characterized by the
presence of a novel TRAF domain at the C terminus, which
consists of a coiled-coil domain, followed by a conserved
TRAF-C domain [57]. The TRAF domain plays an important
role by mediating self-association and upstream interactions
with receptors and other signaling proteins [58]. The N-termi-
nal of most TRAF proteins (TRAF2–6) contains a really in-
teresting new gene finger motif and several zinc finger motif. As
a family of proteins, the TRAFs mediate their actions through
the activation of transcription factors of the NF-B and AP-1
family. However, within the family, each TRAF has evolved to
mediate distinct signal transduction cascades in a divergent
and a convergent manner.
Initially, TRAF6 was thought to be the sole member of this
family to be involved in TLR signaling. TRAF6, a ubiquitin
ligase, can ubiquitinate itself on Lys-63 (K63)-linked polyu-
biquitin chains. Ubiquitination targets proteins for proteolytic
degradation or activation, depending on the lysine that is
modified. For example, polyubiquitination on Lys-48 targets
proteins for adenosine 5-triphosphate-dependent proteolysis
by the 26S proteasome [59]. In contrast, polyubiquitination on
Lys-63 modulates protein function in the absence of degrada-
tion. Polyubiquitination of Lys-63 triggers IKK activation
through an as-yet undefined mechanism [60]. As TRAF6 is not
degraded following ubiquitination, its signaling must be nega-
tively regulated in some manner. It has been shown that the
de-ubiquitination enzyme A20 terminates TLR signaling by
removing ubiquitin moieties from TRAF6 [61]. A20-deficient
macrophages showed enhanced NF-B activity in response to
TLR2, TLR4, and TLR9 ligands.
A number of studies have shown that TLR signaling may be
regulated by modulation of TRAF6 signaling or use of alter-
native TRAF family members. For instance, negative regula-
tion of TRAF6 by -arrestin has been demonstrated [62].
Specifically, it has been shown that -arrestins interact with
TRAF6 in response to LPS and IL-1 stimulation. -Arrestins,
in addition to their established roles in receptor desensitization
and endocytosis, bind to signaling molecules such as the Src
family kinases [63] and the E3 ligase Mdm2 [64, 65]. In terms
of TLR signaling, it has been shown that -arrestins negatively
regulate TLR signaling by preventing oligomerization of
TRAF6, thereby inhibiting its autoubiquitination and
subsequent signaling pathways such as NF-B and AP-1 ac-
tivation [62].
Recently, a number of studies have shown that in addition to
TRAF6, activation of distinct TLRs may result in recruitment
of alternative TRAF family members, thus adding to the diver-
sity and complexity of the TLR signaling pathway. For exam-
ple, a recent study has shown that the C-domain of TRAF1
interacts with the TIR domain of Trif; in fact, TRAF1 inhibited
Trif and TLR3-mediated activation of NF-B, IFN-stimulated
response element, and IFN- promoter activity [66]. Moreover,
it was shown that TRAF1 is cleaved by caspase-8 generating
two fragments, TRAF1(1–163) and TRAF1(164–416), and it is
TRAF1(1–163) that is responsible for its inhibitory effects on
Trif-mediated signaling. Also, Mal and MyD88 interact with
TRAF1, suggesting that TRAF1 may negatively regulate Mal
and MyD88 signaling, although this remains to be fully ex-
plored [66].
TRAF3 has recently been identified as a new component of
TLR signaling, whereby it is recruited along with TRAF6 [67].
Whereas TRAF6 mediates MAPK and IKK, resulting in the
activation of NF-B, and AP-1, resulting in the induction of
proinflammatory cytokines, TRAF3 is dispensible in this pro-
cess. However, TRAF3 is crucial for the recruitment of type 1
IFNs and the anti-inflammatory cytokine IL-10 [67]. TRAF3
also interacts directly with Trif and IRAK-1, as well as the
IRF3/7 kinases TBK1, IKKi, and putative intracellular viral
receptor, protein kinase receptor [67, 68]. Together, these
studies reveal that TRAF3 is a critical adaptor molecule for
Trif-mediated IRF3 activation and type-1 IFN induction in
response to direct TLR activation and direct viral infection.
PERSPECTIVES
Our ability to respond appropriately to pathogenic challenges
is key to our survival, and the TLRs are the first point of contact
that we have with invading organisms. As such, the mecha-
nisms regulating the TLR response must be controlled tightly,
first to respond appropriately to the pathogenic challenge and
second, to prevent excessive activation of the TLR signaling
pathway and thus, to control detrimental/deleterious damage to
the host system following TLR activation. Intricate mecha-
nisms by which TLR signaling may be regulated are revealed.
Protein degradation, sequestration, and compartmentalization
are some of the regulatory mechanisms that have evolved.
Ultimately, greater understanding of the mechanisms behind
TLR signaling will hopefully lead to the development of novel,
therapeutic regimes in the treatment of inflammatory diseases
and autoimmunity.
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